Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Claudia Monaco, of the Kennedy Institute, is the 2015 Oxford-Harrington Scholar.

As a clinician-scientist, Professor Monaco has dedicated her career to the discovery of new treatments for cardiovascular disease (CVD). Her work was pioneering in looking at CVD within the area of inflammation, using a unique approach to test efficacy in human atherosclerosis – a condition where arteries become blocked by fatty substances.

CVD is a big health problem and the second leading cause of death in the UK, representing 28% of all deaths in 2012. In addition, there were more than 1.6 million episodes related to cardiovascular disease in NHS hospitals, with more than £6.8 billion being spent on treating CVD within the NHS in England.

Professor Monaco’s research aims to change standard of care and improve health for people with CVD, by bringing new medicines into the clinical setting.

The Oxford-Harrington Scholarship Programme was set up in 2014 as a partnership between the Harrington Discovery Institute (Cleveland, USA) and the University of Oxford to advance highly promising Oxford supported drug discovery projects.

The rate of drug development is now slower than it used to be, with pharmaceutical companies and investors waiting to invest until the efficiency of a drug has been confirmed. This leaves a gap in the intermediate stages of research and development and has discouraged clinical scientists from pursuing their ideas.

The Oxford-Harrington Scholarship will close this gap by supporting clinical scientists whose ideas have great potential to become new treatments, with pre-clinical drug research and clinical trials in the early stages. It will also provide the drug development infrastructure needed to turn a discovery into a medicine.

The first Oxford-Harrington scholar was Professor Alison Simmons, whose aims were to undertsnad how inflammation damages the gut in Crohn’s disease, a condition that affects 1 in 200 people.

You can read more about the 2015 Oxford-Harrington Scholar here.

 

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Fiona Powrie honoured by British Society for Immunology

Fiona Powrie was one of four researchers from the University of Oxford recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology.

The Kennedy Institute scoops sustainability award

A new roof extension was awarded the 2021 Green Award for Sustainability by the Oxford Preservation Trust alongside a Certificate in the New Building category.

Oxford-Bristol Myers Squibb Fellowships awarded to NDORMS researchers

Researchers from the Kennedy Institute of Rheumatology have been awarded fellowships as part of the Oxford-Bristol Myers Squibb Fellowship Programme. Among six researchers from across NDORMS, the programme provides them with an opportunity to gain exposure to the field of commercial drug discovery and development.

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS